<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174108</url>
  </required_header>
  <id_info>
    <org_study_id>100154</org_study_id>
    <secondary_id>10-H-0154</secondary_id>
    <nct_id>NCT01174108</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells</brief_title>
  <official_title>Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Stem cell transplants from related donors (allogenic stem cell transplants) can be used
           to treat individuals with certain kinds of severe blood diseases or cancers, such as
           severe anemia. Allogenic stem cell transplants encourage the growth of new bone marrow
           to replace that of the recipient. Because stem cell transplants can have serious
           complications, researchers are interested in developing new approaches to stem cell
           transplants that will reduce the likelihood of these complications.

        -  By reducing the number of white blood cells included in the blood taken during the stem
           cell collection process, and replacing them with a smaller amount of white blood cells
           collected prior to stem cell donation, the stem cell transplant may be less likely to
           cause severe complications for the recipient. Researchers are investigating whether
           altering the stem cell transplant donation procedure in this manner will improve the
           likelihood of a successful stem cell transplant with fewer complications.

      Objectives:

      - To evaluate a new method of stem cell transplantation that may reduce the possibly of
      severe side effects or transplant rejection in the recipient.

      Eligibility:

        -  Recipient: Individuals between 4 and 80 years of age who have been diagnosed with a
           blood disease that can be treated with allogenic stem cell transplants.

        -  Donor: Individuals between 4 and 80 years of age who are related to the recipient and
           are eligible to donate blood. OR unrelated donors found through the National Marrow
           Donor Program.

      Design:

        -  All participants will be screened with a physical examination and medical history.

        -  DONORS:

        -  Donors will undergo an initial apheresis procedure to donate white blood cells.

        -  After the initial donation, donors will receive injections of filgrastim to release bone
           marrow cells into the blood.

        -  After 5 days of filgrastim injections, donors will have apheresis again to donate stem
           cells that are present in the blood.

        -  RECIPIENTS:

        -  Recipients will provide an initial donation of white blood cells to be used for research
           purposes only.

        -  From 7 days before the stem cell transplant, participants will be admitted to the
           inpatient unit of the National Institutes of Health Clinical Center and will receive
           regular doses of cyclophosphamide, fludarabine, and anti-thymocyte globulin to suppress
           their immune system and prepare for the transplant.

        -  After the initial chemotherapy, participants will receive the donated white blood cells
           and stem cells as a single infusion.

        -  After the stem cell and white blood cell transplant, participants will have regular
           doses of cyclosporine and methotrexate to prevent rejection of the donor cells.
           Participants will have three doses of methotrexate within the week after the transplant,
           but will continue to take cyclosporine for up to 4 months after the transplant.

        -  Participants will remain in inpatient care for up to 1 month after the transplant, and
           will be followed with regular visits for up to 3 years with periodic visits thereafter
           to evaluate the success of the transplant and any side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (aHSCT) can cure patients with a variety
      of bone marrow failure syndromes (BMFS) including severe aplastic anemia (SAA), paroxysmal
      nocturnal hemoglobinuria (PNH) or myelodysplastic syndrome (MDS) associated with cytopenias.
      Patients with BMFS have traditionally been transplanted with bone marrow (BM) as a stem cell
      source. Although chronic graft versus host disease (cGVHD) occurs less commonly with BM
      compared to filgrastim (G-CSF) mobilized peripheral blood stem cell (PBSC) transplants, BM
      allografts have lower CD34+ progenitor cell numbers, which increases the risk of graft
      rejection in heavily transfused BMFS patients to 15-20%. To overcome this risk, our group
      developed a novel transplant approach for patients at high risk for graft rejection that
      utilized cyclophosphamide, fludarabine and anti-thymocyte globulin (ATG) conditioning
      followed by infusion of a CD34+ cell rich, T-cell replete G-CSF mobilized PBSC allograft.
      Remarkably, in 56 consecutive BMFS patients who had multiple risk factors for graft rejection
      who underwent this transplant approach, graft rejection did not occur, with all patients
      achieving complete donor lymphohematopoietic chimerism. Unfortunately, recipients of G-CSF
      mobilized PBSC had a higher incidence of cGVHD than has historically been observed with BM
      transplantation (72% vs. 50% cumulative incidence of cGVHD at 1 year respectively). G-CSF
      mobilized PBSC transplants contained approximately a 20 fold higher dose of T-cells that had
      undergone a TH-2 type cytokine polarization, a factor which likely contributed to this high
      incidence of cGVHD. In this protocol, we attempt to prevent graft failure and to reduce the
      incidence of cGVHD by transplanting high numbers of CD34+ selected PBSC co-infused with a
      reduced dose of non-mobilized donor T-cells that have not undergone a TH-2 cytokine
      polarization.

      Subjects with BMFS at high risk for graft rejection will undergo allogeneic stem cell
      transplantation from an HLA identical sibling or match unrelated donor using the identical
      conditioning regimen utilized in protocol 99- H-0050. Using the Miltenyi CliniMACs system,
      recipients will receive an allograft on day 0 containing donor CD34+ cells that have been
      positively selected and T-cell depleted following G-CSF mobilization (goal CD34+ cell dose of
      5 x 106 CD34+ cells /kg recipient) combined with 2 x 107 cells/kg of non-mobilized CD3+
      T-cells previously collected and cryopreserved from the same donor by apheresis prior to
      G-CSF mobilization.

      Primary objective: To evaluate whether administering a CD34+ selected, T-cell depleted
      peripheral blood stem cell graft with a concomitant infusion of non-mobilized donor T-cells
      at a dose that matches the T-cell dose that is infused in historical bone marrow transplant
      cohorts will reduce the incidence of cGVHD at 1 year to that observed with a conventional
      bone marrow transplant (50%) without increasing the risk of graft failure. This trial design
      will allow the trial to stop early if it is unlikely that we have reduced the proportion of
      one year cGVHD to 50% or if the combined event rate for failed donor engraftment or treatment
      related mortality (TRM) at day 100 exceeds 20%.

      The primary endpoint of this study will be cGVHD at day 365.

      Secondary end points include transplant related mortality, engraftment, degree of donor-host
      chimerism, incidence of acute and chronic graft versus host disease (cGVHD), transplant
      related morbidity and overall survival. Health related quality of life will also be assessed
      as a secondary outcome measure pre-transplant, 30 and 100 days post transplant, and every 6
      months until 5 years post transplant.

      Subjects with BMFS at high risk for graft rejection will undergo allogeneic stem cell
      transplantation from an HLA identical sibling or match unrelated donor using the identical
      conditioning regimen utilized in protocol 99-H-0050. Using the Miltenyi CliniMACs system,
      recipients will receive an allograft on day 0 containing donor CD34+ cells that have been
      positively selected and T-cell depleted following G-CSF mobilization (goal CD34+ cell dose of
      5 times 10(6) CD34+ cells /kg recipient) combined with 2 times 10(7) cells/kg of
      non-mobilized CD3+ T-cells previously collected and cryopreserved from the same donor by
      apheresis prior to G-CSF mobilization.

      Primary objective: To evaluate whether administering a CD34+ selected, T-cell depleted
      peripheral blood stem cell graft with a concomitant infusion of non-mobilized donor T-cells
      at a dose that matches the T-cell dose that is infused in historical bone marrow transplant
      cohorts will reduce the incidence of cGVHD at 1 year to that observed with a conventional
      bone marrow transplant (50 percent) without increasing the risk of graft failure. This trial
      design will allow the trial to stop early if it is unlikely that we have reduced the
      proportion of one year cGVHD to 50 percent or if the combined event rate for failed donor
      engraftment or treatment related mortality (TRM) at day 100 exceeds 20 percent.

      The primary endpoint of this study will be cGVHD at day 365.

      Secondary end points include transplant related mortality, engraftment, degree of donor-host
      chimerism, incidence of acute and chronic graft versus host disease (GVHD), transplant
      related morbidity and overall survival. Health related quality of life will also be assessed
      as a secondary outcome measure pre-transplant, 30 and 100 days post transplant and every 6
      months until 5 years post transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2011</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint of this study is chronic GVHD by one year.</measure>
    <time_frame>1 year</time_frame>
    <description>chronic GVHD</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <condition>MDS (Myelodysplastic Syndrome)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target doses: CD34+ cells 8 x 106/kg; CD3+ cells 2 x 107/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Miltenyi CD34 Reagent System</intervention_name>
    <description>The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Donor derived G-CSF mobilized PBC</intervention_name>
    <description>Cell Therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Recipient:

               -  Patients diagnosed with one of the following hematologic diseases which are
                  associated with reasonable longevity, shown to be curable by allogeneic BMT but
                  where concern for a high procedural mortality with conventional BMT may delay or
                  prevent such treatment:

                    -  1) Paroxysmal nocturnal hemoglobinuria (PNH) associated with
                       life-threatening thrombosis, and/or cytopenia, and/or transfusion dependence
                       and/or recurrent and debilitating hemolytic crisis

                    -  2) Severe aplastic anemia (SAA) or pure red cell aplasia (PRCA [acquired or
                       congenital]) associated with transfusion dependence and/or neutropenia in
                       patients who are not candidates for, or who have failed immunosuppressive
                       therapy

                    -  3) Refractory anemia (RA) or RARS MDS patients who have associated
                       transfusion dependence and/or neutropenia.

               -  Ages 4 to 80 (both inclusive), and weight &gt;18kg

               -  Availability of HLA identical or single HLA locus mismatched family donor or
                  10/10 matched unrelated donor at the allelic level (HLA alleles A, B, C, DR, and
                  DQ).

               -  9/10 donors where all the HLA sequences have the same antigen/peptide binding
                  domains in key exons to the patient. This can result in identical protein
                  sequences between patient and donor. Allele mismatches in p and g groups can be
                  considered acceptable due to the exact matching which exists in the binding
                  domains.

               -  Telomere Length Testing

               -  Germline/Inherited gene panel in patients where a suspicion for a familial bone
                  marrow failure syndrome (BMFS) exists, hTERC and hTERT, GATA2 mutation testing
                  will be performed on protocol 04-H-0012 or performed elsewhere prior to enrolling
                  on 04-H-0012.

        EXCLUSION CRITERIA:

        -Recipient: any of the following

          -  Major anticipated illness or organ failure incompatible with survival from PBSC
             transplant

          -  Diffusion capacity of carbon monoxide (DLCO) &lt;40% predicted (patients under the age of
             10 may be excluded from this criterion if they have difficulty performing the test
             correctly and thus are unable to have their DLCO assessed) using DL Adj and DL/VA/Adj.

          -  Left ventricular ejection fraction &lt;40% (evaluated by ECHO) or &lt;30% (evaluated by
             MUGA)

          -  Serum creatinine greater than 2.5mg/dl or creatinine clearance less than 50 ml/min by
             24 hr urine collection

          -  Serum bilirubin greater than 4 mg/dl, transaminases greater than 5 times the upper
             limit of normal

          -  Pregnant or lactating

          -  Fanconi s anemia

          -  ECOG performance status of 3 or more (See Bone &amp; Marrow Transplant Consortium
             Supportive Care Guidelines for HSCT Recipients)

          -  Other malignant diseases liable to relapse or progress within 5 years, with the
             exception of a separate hematologic malignancy where allogeneic stem cell transplant
             has been shown to be potentially curative.

          -  Presence of an active infection not adequately responding to appropriate therapy.

          -  Inability to comprehend the investigational nature of the study and provide informed
             consent. The procedure will be explained to subjects age 8 -17 years with formal
             consent being obtained from parents or legal guardian.

        INCLUSION CRITERIA:

        -Related Donor:

          -  Related donor deemed suitable and eligible, and willing to donate, per clinical
             evaluations who are additionally willing to donate blood for research. Related donors
             will be evaluated in accordance with existing Standard NIH Policies and Procedures for
             determination of eligibility and suitability for clinical donation. Note that
             participation in this study is offered to all related donors, but is not required for
             a donor to make a stem cell donation, so it is possible that not all related donors
             will enroll onto this study

          -  Age greater than or equal to 4 and less than or equal to 80 years old

        INCLUSION CRITERIA &amp; EXCLUSION CRITERIA: Unrelated Donor

        -The NMDP unrelated donor inclusion criteria will be used as outlined in document (link).
        Donor eligibility will be completed per NMDP standards and in accordance with most recent
        and stringent FDA guidelines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard W Childs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Cook, R.N.</last_name>
    <phone>(301) 402-5609</phone>
    <email>lc224a@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland at Baltimore/MPRC</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Hardy, M.D.</last_name>
      <phone>410-328-1230</phone>
      <email>nhardy12@umm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2010-H-0154.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995 Jun 15;85(12):3367-77. Review.</citation>
    <PMID>7780125</PMID>
  </reference>
  <reference>
    <citation>Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997 May 8;336(19):1365-72. Review.</citation>
    <PMID>9134878</PMID>
  </reference>
  <reference>
    <citation>Zoumbos NC, Gasc√≥n P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med. 1985 Jan 31;312(5):257-65.</citation>
    <PMID>2981406</PMID>
  </reference>
  <verification_date>May 12, 2020</verification_date>
  <study_first_submitted>July 31, 2010</study_first_submitted>
  <study_first_submitted_qc>July 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome (MDS)</keyword>
  <keyword>Severe Aplastic Anemia</keyword>
  <keyword>Pure Red Cell Aplasia</keyword>
  <keyword>Paroxysmal Nocturnal Hemoglobinuria (PNH)</keyword>
  <keyword>Miltenyi CD34 Reagent System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

